Mounjaro® (Tirzepatide) Adoption in India: Physician Survey Insights
A recent survey of 105 Indian physicians including endocrinologists, diabetologists, general practitioners, and internal medicine specialists offers key insights into the awareness, adoption, and perception of Mounjaro® (tirzepatide) in the management of type 2 diabetes (T2D) and obesity done by SPER Market Research Pvt Ltd. Key observations of the survey are:
Respondent Profile
- Physicians averaged 14.6 years of experience, seeing ~142 patients per week, with 52% having T2D and 38% with obesity.
- Practice settings included private clinics (41%), private hospitals (33%), and government facilities (14%).
Awareness & Knowledge
- 85% of respondents are aware of Mounjaro®, with 72% correctly identifying its dual GIP + GLP-1 mechanism.
- Main sources of awareness include medical representatives (64%), conferences/CME (52%), and scientific publications (47%).
Markets covered
Prescribing Trends & Uptake
- 31% actively prescribe Mounjaro®, with an additional 24% planning to start within 6 months.
- Current uptake remains low, with ~75% of eligible patients receiving it in <10% of cases.
- Primarily prescribed for T2D with obesity (74%), with key adoption drivers including superior weight reduction (78%) and improved glycemic control (65%).
Barriers & Concerns
- High cost (83%) and limited availability (62%) are major barriers.
- Physicians cite gaps in Indian guideline inclusion (47%) and long-term safety data (33%) as additional concerns.
- Safety perception is largely favorable, with 74% rating tolerability as acceptable or highly favorable.
Comparative Perception
- Mounjaro® is perceived as superior to Ozempic/Wegovy (72%) and Saxenda (43%) in efficacy, with weight maintenance (67%) and patient satisfaction (63%) as strong differentiators.
- Cost-effectiveness remains a concern, with 45% rating it inferior to alternatives.
Physician Feedback
- Greater adoption depends on affordability, broader access, and real-world Indian evidence.
- Rising patient interest and acceptance of injectable therapies indicate growing readiness for advanced obesity and diabetes management.
Future Outlook
- 65% of physicians anticipate moderate-to-strong adoption growth over the next 12 months, contingent on price reduction (72%), local clinical data (58%), and guideline inclusion (53%).
- Overall, Mounjaro® is viewed as a promising game-changer (38%), with 42% considering it early yet promising.
Conclusion
Mounjaro® is recognized by Indian clinicians as an effective dual-action therapy for T2D and obesity. While adoption is currently limited by cost and accessibility, physicians remain optimistic about its potential, particularly with supportive pricing, guideline alignment, and local data initiatives.
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
